Radius Health Announces Expansion of its Bone Health Business Through the Exclusive Licensing of U.S. Rights to BINOSTO® for Osteoporosis

BINOSTO® (alendronate sodium) effervescent tablet complements currently marketed product, TYMLOS® (abaloparatide) injection, for the treatment of Osteoporosis

BOSTON––(BUSINESS WIRE)––Radius Health, Inc. (“Radius” or the “Company”), a specialty biopharmaceutical company focused on bone health and related areas, announced today that it has entered into an exclusive licensing and distribution agreement with EffRx Pharmaceuticals, S.A. (“EffRx”), for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution.

BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO® provides an important once-weekly treatment option, particularly for patients with osteoporosis who may not be able to take alendronate tablets. Radius currently markets TYMLOS® for the treatment of osteoporosis in the U.S. and has commercial partnerships in the E.U., U.K., Australia, Japan, and other regions. BINOSTO® expands Radius’ presence in the treatment of bone health with a second product for the approximately 10 million people in the U.S. living with osteoporosis.

Scott Briggs, Chief Executive Officer of Radius, commented, “We are pleased to offer another product to support the needs of patients who are living with osteoporosis. We have seen strong growth of TYMLOS® in the last year, and while it will remain a primary focus, BINOSTO® addresses an important unmet need particularly for patients who have difficulty swallowing pills.”

Ed Cinca, Chief Commercial Officer of Radius added, “The addition of BINOSTO® along with our currently marketed product TYMLOS® will allow Radius to expand its product offerings to healthcare providers treating osteoporosis. Given our success with TYMLOS®, we believe that we are well-positioned to support the future growth of BINOSTO®, which has been particularly successful in markets outside the U.S. We look forward to the introduction of BINOSTO® in the coming months.”

Under the terms of the agreement, EffRx will grant Radius an exclusive, royalty bearing license to BINOSTO® in the U.S. and will also supply product to Radius.

About BINOSTO®:
BINOSTO® (alendronate sodium) is an effervescent tablet for oral solution indicated for the treatment of osteoporosis in postmenopausal women and treatment to increase bone mass in men with osteoporosis. BINOSTO® has been shown to increase bone mass and reduce the incidence of fractures. Each dissolving tablet contains the same strength ingredient as once weekly Fosamax®. BINOSTO® is administered once weekly. The most common adverse events associated with BINOSTO® include abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, and nausea. Please see the full prescribing information for details, which can be found at www.binosto.com.

About Radius:
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in bone health and related areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the increase in bone density in men with osteoporosis at high risk for fracture.

Contact:
Sara Goldberg: Lead, Communications
Email: [email protected]
Phone: +1 (631) 379-8374